Checkpoint Inhibitors: Trial Design and Challenges
Checkpoint Inhibitors: Trial Design and Challenges Designing and Managing Clinical Trials for Checkpoint Inhibitors Introduction to Checkpoint Inhibitors Checkpoint inhibitors have transformed cancer treatment by unleashing the immune system to attack tumor cells. Targeting pathways such as PD-1, PD-L1, and CTLA-4, these agents have shown durable responses across multiple malignancies, including melanoma, non-small cell lung…
Read More “Checkpoint Inhibitors: Trial Design and Challenges” »